文献速递乳腺癌

我们在统计学假设上是否想当然了?来自ALTTO试验的教训

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.
PubMed 文献 · Ann Oncol · 2019-01-01

本文以入组8381例人表皮生长因子受体2阳性早期乳腺癌患者的ALTTO随机对照试验为例,说明事件率、比例风险等常规统计学假设如何影响随机对照试验结果的报告,并对无效性终止规则、亚组分析、Cox模型、事件累积与把握度、多臂试验的Ⅰ类错误控制提出五点结论。

要点

  • 因无效而提前终止可保护患者安全,但因疗效提前终止可能造成误导,短期结果未必代表长期疗效。
  • 亚组间生物学差异可导致临床治疗效应不同,应预先设定主要亚组分析并限定于已知受靶向治疗影响的终点。
  • 若未仔细考虑风险的非比例性,常规以Cox模型为重点的分析可能造成误导。

核心结论

  • 无效性终止规则对保护患者安全很重要,但因疗效提前终止可能造成误导,短期结果未必意味着长期疗效。
  • 亚组间具有生物学重要性的差异可驱动临床不同的治疗效应,应加以考虑,例如预先设定主要亚组分析,并将终点限定于已知受靶向治疗影响的事件。
  • 若不仔细考虑风险的非比例性,通常以Cox模型为重点的分析可能造成误导;加速失效时间模型的结果表明,给予后期事件更多权重(如 log rank 检验中所为)可影响结论。
  • 认为累积更多事件总能确保把握度增加的假设需要受到质疑,应考虑风险率与风险比随时间的变化。
  • 在设有多个实验臂的临床试验中,要求家族wiseⅠ类错误控制在≤5%会阻碍旨在回答不止一个问题的研究设计。

研究设计与样本

  • 本文使用近期报告的ALTTO随机对照试验的经验,该试验于2007年6月至2011年7月入组8381例人表皮生长因子受体2阳性早期乳腺癌患者。
  • 试验注册号:clinicaltrials.gov Identifier NCT00490139。

主要发现

  • 因疗效提前终止可能造成误导,因为短期结果未必意味着长期疗效。
  • 亚组间具有生物学重要性的差异可驱动临床不同的治疗效应。
  • 加速失效时间模型的结果表明,给予后期事件更多权重(如 log rank 检验中所为)可影响结论。
  • 认为累积更多事件总能确保把握度增加的假设需要受到质疑,应考虑风险率与风险比随时间的变化。
  • 要求家族wiseⅠ类错误控制在≤5%会阻碍旨在回答不止一个问题的研究设计。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Design, conduct, and analysis of randomized clinical trials (RCTs) with time to event end points rely on a variety of assumptions regarding event rates (hazard rates), proportionality of treatment effects (proportional hazards), and differences in intensity and type of events over time and between subgroups. DESIGN AND METHODS: In this article, we use the experience of the recently reported Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) RCT, which enrolled 8381 patients with human epidermal growth factor 2-positive early breast cancer between June 2007 and July 2011, to highlight how routinely applied statistical assumptions can impact RCT result reporting. RESULTS AND CONCLUSIONS: We conclude that (i) futility stopping rules are important to protect patient safety, but stopping early for efficacy can be misleading as short-term results may not imply long-term efficacy, (ii) biologically important differences between subgroups may drive clinically different treatment effects and should be taken into account, e.g. by pre-specifying primary subgroup analyses and restricting end points to events which are known to be affected by the targeted therapies, (iii) the usual focus on the Cox model may be misleading if we do not carefully consider non-proportionality of the hazards. The results of the accelerated failure time model illustrate that giving more weight to later events (as in the log rank test) can affect conclusions, (iv) the assumption that accruing additional events will always ensure gain in power needs to be challenged. Changes in hazard rates and hazard ratios over time should be considered, and (v) required family-wise control of type 1 error ≤ 5% in clinical trials with multiple experimental arms discourages investigations designed to answer more than one question. TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT00490139.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Holmes EM, Bradbury I, Williams LS, et al. Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial. Ann Oncol. 2019. PMID: 31240310. doi:10.1093/annonc/mdz195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。